FOLFIRINOX as First-Line Treatment for Unresectable Acinar Cell Carcinoma of the Pancreas: A Case Report

DOI HANDLE PDF PubMed 被引用文献3件
  • U. Schempf
    Department of Internal Medicine I, Medical University Hospital, Tuebingen, Germany
  • B. Sipos
    Institute of Pathology, University of Tuebingen, Tuebingen, Germany
  • C. König
    Department for Diagnostic and Interventional Radiology, University of Tuebingen, Tuebingen, Germany
  • N. Malek
    Department of Internal Medicine I, Medical University Hospital, Tuebingen, Germany
  • M. Bitzer
    Department of Internal Medicine I, Medical University Hospital, Tuebingen, Germany
  • R. Plentz
    Department of Internal Medicine I, Medical University Hospital, Tuebingen, Germany

書誌事項

公開日
2014-02-13
DOI
  • 10.1055/s-0033-1356439
公開者
Georg Thieme Verlag KG

この論文をさがす

説明

Pancreatic acinar cell carcinoma (ACC) is a rare, aggressive variant of pancreatic ductal adenocarcinoma. Surgery is the only curative treatment option and protocols for palliative chemotherapies in this context are not standardized yet. We reported a 63-year-old white male patient who had painless jaundice, weight loss, elevated bilirubin, and a mass of the pancreatic head as well as liver metastasis. Core biopsy revealed the diagnosis of ACC. Therapy with FOLFIRINOX resulted in a significant decrease of the primary tumor and regressiveness of a liver metastasis after chemotherapy. Our report suggests that pancreatic ACC treated by FOLFIRINOX is well tolerated and might be superior to other single chemotherapies in this rare tumor disease.

収録刊行物

被引用文献 (3)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ